Literature DB >> 1037209

The effect of colestipol on digitoxin plasma levels.

R J van Bever, A M Duchateau, B F Pluym, F W Merkus.   

Abstract

The effect of colestipol (colestipol hydrochloride; U-26 597 A), a copolymer of tetraethylenepentamine and epichlorhydrine, on plasma digitoxin levels has been investigated. Recently, it has been stated that colestipol decreases the enterohepatic circulation and the plasma half-life of digitoxin. Colestipol was administered to 11 patients having a digitoxin plasma level which is generally accepted to be above the therapeutic range (greater than 40 ng/ml). The elimination rate of digitoxin measured by serial radioimmunoassay in these colestipol treated patients was compared with the elimination rate of digitoxin in 11 patients not treated with colestipol. The results of this study did not demonstrate a significant difference in the mean (+/- S.D.) digitoxin plasma half-life between the colestipol treated (6.3 +/- 1.3 days) and the non-colestipol treated patients (6.8 +/- 1.0 days).

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1037209

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  6 in total

1.  Clinical pharmacokinetics of digitoxin.

Authors:  D Perrier; M Mayersohn; F I Marcus
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

2.  Effects of resins and activated charcoal on the absorption of digoxin, carbamazepine and frusemide.

Authors:  P J Neuvonen; K Kivistö; E L Hirvisalo
Journal:  Br J Clin Pharmacol       Date:  1988-02       Impact factor: 4.335

Review 3.  Drug interactions with digitalis glycosides.

Authors:  P F Binnion
Journal:  Drugs       Date:  1978-05       Impact factor: 9.546

4.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

Review 5.  Colestipol: a review of its pharmacological properties and therapeutic efficacy in patients with hypercholesterolaemia.

Authors:  R C Heel; R N Brogden; G E Pakes; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-03       Impact factor: 9.546

Review 6.  Adverse effects of hypolipidaemic drugs.

Authors:  L C Knodel; R L Talbert
Journal:  Med Toxicol       Date:  1987 Jan-Feb
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.